The Immune Landscape in Women Cancers.
Breast cancer
Dendritic cells (DC)
Immunotherapy
Macrophages
Myeloid-derived suppressor cells (MDSC)
Neoadjuvant therapy (NACT)
Ovarian cancer
Regulatory T cells (Tregs)
T cells
Tumor infiltrating lymphocytes (TILs)
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
28
3
2020
pubmed:
28
3
2020
medline:
4
9
2020
Statut:
ppublish
Résumé
In this chapter, we summarize the latest findings in the field of immuno-oncology of women cancers, particularly ovarian and breast tumors. We describe the relationship between immune parameters and clinical outcomes by evaluating the contribution of different players of the tumor microenvironment, with a particular focus on different immune cell subsets and their essential role during the development of the disease, the response to standard chemotherapy, and to emerging immunotherapeutic approaches. By reviewing the molecular and genetic features of ovarian and breast cancer subtypes, we report on the multitude of factors influencing treatment outcome, with a particular interest on the possible influence of the immune system (i.e., tumor infiltrating lymphocytes, T cells, regulatory T cells, myeloid-derived suppressor cells, dendritic cells, macrophages, B cells, tumor-associated neutrophils). Finally, we discuss emerging immune targets and novel therapeutic modalities that are likely to profoundly influence clinical outcome and prognosis of breast and ovarian cancers in the next future.
Identifiants
pubmed: 32215872
doi: 10.1007/978-3-030-38862-1_8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM